Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Jeremy Samuel Faust, Ashish Kumar, Jui Shah, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1257-1264
Closed Access | Times Cited: 18

Showing 18 citing articles:

A novel nanocomposite drug delivery system for SARS-CoV-2 infections
Uday Chintapula, Shazeed-Ul Karim, Priyanka Raghunathan Iyer, et al.
Nanoscale Advances (2024) Vol. 6, Iss. 15, pp. 3747-3758
Open Access | Times Cited: 6
Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study
Junyi Sun, Mengzhao Yang, Daoke Yao, et al.
View (2025)
Open Access
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
Guozhang Lin, Yuchen Wei, Zihao Guo, et al.
Respiratory Research (2025) Vol. 26, Iss. 1
Open Access
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019
Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 718-718
Open Access | Times Cited: 3
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Sydney Paltra, Tim Conrad
Advances in respiratory medicine (2024) Vol. 92, Iss. 1, pp. 66-76
Open Access | Times Cited: 2
Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune‐suppressive drugs: A nationwide cohort study of US Veterans
Sonia T. Anand, Austin D. Vo, Jennifer La, et al.
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 5
Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection
Rushin Patel, Sourbha S. Dani, Sumanth Khadke, et al.
JACC Advances (2024) Vol. 3, Iss. 6, pp. 100961-100961
Open Access | Times Cited: 1
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert)
Isolde Sommer, Andreea Dobrescu, Emma Persad, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8
Closed Access | Times Cited: 1
Racial and Ethnic Disparities in Age-Specific All-Cause Mortality During the COVID-19 Pandemic
Jeremy Samuel Faust, Benjamin Renton, Tasce Bongiovanni, et al.
JAMA Network Open (2024) Vol. 7, Iss. 10, pp. e2438918-e2438918
Open Access | Times Cited: 1
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
Adeel A. Butt, Yan Peng, Obaid S. Shaikh, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 1, pp. 147-154
Open Access | Times Cited: 4
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study
Giuseppe A. Ramirez, Maria Gerosa, Chiara Bellocchi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 3
Age-Specific All-Cause Mortality Disparities by Race and Ethnicity During the COVID-19 Pandemic
Jeremy Samuel Faust, Benjamin Renton, Tasce Bongiovanni, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico
María Elena Camacho-Moll, Ana María Salinas‐Martínez, Minna Wu, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 7, pp. 102444-102444
Open Access
Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
Zequn Zheng, Jiaozhi Zhou, Yongfei Song
PubMed (2024) Vol. 49, Iss. 5, pp. 275-285
Closed Access
The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer
Wan‐Hsuan Hsu, Bo-Wen Shiau, Ya‐Wen Tsai, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 8, pp. 102465-102465
Open Access
Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18–60 years
Wan‐Hsuan Hsu, Bo-Wen Shiau, Ya‐Wen Tsai, et al.
Expert Review of Anti-infective Therapy (2024), pp. 1-9
Closed Access
Emerging therapeutic options
Anu Mariam Saji, Sonu Abraham, Sarju Ganatra
Elsevier eBooks (2024), pp. 257-274
Closed Access
Page 1

Scroll to top